Using positron emission tomography with [18F]FDG to predict tumor behavior in experimental colorectal cancer

Neoplasia

Volumn 3, Issue 3, 2001, Pages 189-195

  Burt, Bryan M ^a   Humm, John L ^a   Kooby, David A ^a   Squire, Olivia D ^a   Mastorides, Stephen ^a   Larson, Steve M ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

FDG; GLUT; Hexokinase; PET; Tumor growth

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER; HEXOKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; COLORECTAL CANCER; DEPHOSPHORYLATION; DRUG ACCUMULATION; DRUG TUMOR LEVEL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RAT;

EID: 0034885978     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900147     Document Type: Article

References (57)

1. On the origin of cancer cells
2. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers
3. Intratumoral distribution of tritiated FDG in breast carcinoma: Correlation between Glut-1 expression and FDG uptake
4. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors
5. 18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice
6. Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages
7. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase
8. Enzymology of cancer cells (second of two parts)
9. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: Characterization of tumor and assessment of effect of treatment
10. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors
11. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET
12. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer
13. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose
14. Utility of 18F-FDG-PET scanning on selection of patients for resection of hepatic colorectal metastases
15. Recurrent rectal cancer and scar: Differentiation with PET and MR imaging
16. Lung cancer proliferation correlates with [F-18] fluorodeoxyglucose uptake by positron emission tomography
17. (F-18)fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma
18. Preoperative evaluation of 54 gliomas by PET with fluorine- 18-fluorodeoxyglucose and/or carbon-11 methionine
19. Metabolic imaging of human extremity musculoskeletal tumors by PET
20. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity
21. PET study of intracranial meningiomas: Correlation with histopathology, cellularity and proliferation rate
22. Fluorodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors
23. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-I (G207)
24. Changes in FDG tumor uptake during and after radiation therapy in a rodent tumor xenograft
25. Performance characteristics of a whole-body PET scanner
26. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding
27. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
28. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
29. Overexpression of GLUT1 and GLUT3 in stage 1 non-small cell lung carcinoma is associated with poor survival
30. Glucose catabolism in cancer cells: Amplification of the gene encoding type II hexokinase
31. 18F]fluorodeoxyglucose in recurrent colorectal cancer
32. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver
33. 18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver
34. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models
35. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models
36. Accumulation with expressions of glucose transporter-1 and hexokinase in human cancer cell lines
37. Variable expression of Glut-1 and hexokinase in human breast and lung cancer
38. Regulation of glucose-transporter gene expression in vitro and in vivo
39. Glut-1 and hexokinase expression: Relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture
40. Hexokinase, differentiation and growth rates of transplanted rat tumors
41. Comparative biochemistry of hepatomas: IV. Isotope studies of glucose and fructose metabolism in liver tumors of different growth rates
42. GLUT1 expression in human breast carcinoma: Correlation with known prognostic markers
43. Growth factors rapidly induce expression of the glucose transporter gene
44. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer
45. Colon carcinoma cells switch their response to transforming growth factor beta 1 with tumor progression
46. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer
47. Glucose-6-phosphatase activity in normal, precancerous, and neoplastic tissues
48. Comparative biochemistry of hepatomas: III, Carbohydrate enzymes in liver tumors of different growth rates
49. Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation
50. Hexokinase isoenzyme patterns of human uterine tumors
51. Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line
52. Complete amino acid sequences of the type II isozyme of rat hexokinase, deduced from the cloned cDNA: Comparison with a hexokinase from Novikoff ascites tumor
53. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: A PET study
54. FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy
55. Positron emission tomography using [(18)F]fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy
56. 18F]-D-glucose